Incyte (INCY) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Incyte (INCY) Misses Q1 EPS by 1c

Incyte (INCY) Price Target Lifted to $107 at Brean Capital; 'Broad And Robust Pipeline'

April 30, 2015 12:34 PM EDT

Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Incyte (NASDAQ: INCY) to $107.00 (from $84.00), citing a broad and robust pipeline.

Aschoff commented, "US Jakafi sales of $115.3 million included meaningful contribution from PV and beat consensus of $112.4 million. Ex-US Jakafi royalties of $15.7 million slightly missed consensus of $16.1 million. The 9% QoQ increase in Jakafi net sales was driven by 8% unit... More

Incyte's (INCY) Hodgkin Lymphoma Treatment Receives FDAOrphan Drug Designation

April 30, 2015 9:07 AM EDT

Incyte (NASDAQ: INCY) received orphan drug Designation for treatment of Hodgkin lymphoma. The FDA site on the designation is here.

... More